Terri Wilder, MSW July 29, 2019 Conference Center at the 10th IAS Conference on HIV Science (IAS 2019), Mexico City, Mexico. International AIDS Society / Steve Forrest / Staff Photos One of the most anticipated studies whose results were presented at the International AIDS Society Conference […]
July 28, 2019. It was an excellent and well-run conference, with one minor complaint. But more on that later… As for the content, here’s a Really Rapid Review® of the highlights: • The risk of neural tube defects in babies born to women who conceived while receiving dolutegravir
Quick Review – NIC 2019 Mexico City by Paul Sax Read More »
Liz Highleyman August 2, 2019 Young adults with vertically transmitted HIV and hepatitis C virus (HCV) coinfection can be easily cured with direct-acting antivirals (DAAs), but some already have advanced liver damage by the time they receive treatment, researchers reported at the 10th International AIDS Conference.
By: Elias El Hage In the context of the 10th Congress of the International AIDS Society 2019, which took place in Mexico City from July 21 to 24, we interviewed the regional director of UNAIDS for Latin America and the Caribbean, César Núñez, who was present at the satellite event entitled: “The
PrEP programs and recruitment Krishen Samuel July 30, 2019 Valdiléa Veloso of ImPrEP at IAS 2019. Photo by Roger Pebody. More than 5,000 men who have sex with men and transgender women have enrolled in the ImPrEP demonstration project in Brazil, Mexico, and Peru, with early results showing good levels of
Same-day PrEP initiation feasible and safe in Latin America Read More »
By: Elias El Hage During the 10th International AIDS Society Conference 2019, held in Mexico City from July 21-24, we interviewed Temistocles Villanueva Ramos, federal deputy for Morena, who participated in the program “Learning and Sharing the Power of
Temistocles Villanueva Ramos: "I came out as HIV-positive" Read More »
Dual therapy with dolutegravir works well for both first-line and maintenance treatments. Liz Highleyman, July 29, 2019. Pedro Cahn at IAS 2019. Photo by Liz Highleyman. A combination of two drugs, dolutegravir and lamivudine (the drugs in the Dovato co-formulation), continued to suppress viral load, as well as a
Treatment simplification strategies. Read More »
Liz Highleyman July 29, 2019 Image credit: ViiV Healthcare The new HIV insertion inhibitor, fostemsavir, continues to maintain viral suppression in more than half of people with extensive prior treatment experience and highly resistant virus, according to a report at the 10th Society Conference
Rescue therapy with fostemsavir continues to look good at 96 weeks. Read More »
IAS 2019 A novel pharmacological mechanism of action, the use of dual therapies that can replace the usual antiretroviral regimens, and changes in administration schedules that allow for spacing out treatments are some of the advances being explored in the approach to HIV/AIDS. Editorial Staff July 26, 2019 Regarding research on dual therapy, two
New treatment regimens could change the approach to HIV Read More »
July 26, 2019 Diana Ernst, RPh The data were presented at the 10th International AIDS Society Conference on HIV Science (NIC 2019). Results from a sub-analysis of the DISCOVER trial showed that Descovy therapy (emtricitabine and tenofovir alafenamide), when used for pre-exposure prophylaxis,
